In vitro- resistens mod moxifloxacin udvikles langsomt via trinvise processer medieret af target- site - mutationer i begge type II topoisomeraser, DNA gyrase og topoisomerase IV.
In vitro resistance to moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV.